AU2003300862A8 - Modulation of endothelial lipase expression - Google Patents

Modulation of endothelial lipase expression

Info

Publication number
AU2003300862A8
AU2003300862A8 AU2003300862A AU2003300862A AU2003300862A8 AU 2003300862 A8 AU2003300862 A8 AU 2003300862A8 AU 2003300862 A AU2003300862 A AU 2003300862A AU 2003300862 A AU2003300862 A AU 2003300862A AU 2003300862 A8 AU2003300862 A8 AU 2003300862A8
Authority
AU
Australia
Prior art keywords
modulation
endothelial lipase
lipase expression
expression
endothelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003300862A
Other versions
AU2003300862A1 (en
Inventor
Kenneth W Dobie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU2003300862A1 publication Critical patent/AU2003300862A1/en
Publication of AU2003300862A8 publication Critical patent/AU2003300862A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
AU2003300862A 2002-12-12 2003-12-11 Modulation of endothelial lipase expression Abandoned AU2003300862A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/319,915 US7507808B2 (en) 2002-12-12 2002-12-12 Modulation of endothelial lipase expression
US10/319,915 2002-12-12
PCT/US2003/039436 WO2004055162A2 (en) 2002-12-12 2003-12-11 Modulation of endothelial lipase expression

Publications (2)

Publication Number Publication Date
AU2003300862A1 AU2003300862A1 (en) 2004-07-09
AU2003300862A8 true AU2003300862A8 (en) 2004-07-09

Family

ID=32506740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003300862A Abandoned AU2003300862A1 (en) 2002-12-12 2003-12-11 Modulation of endothelial lipase expression

Country Status (3)

Country Link
US (3) US7507808B2 (en)
AU (1) AU2003300862A1 (en)
WO (1) WO2004055162A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
KR101885383B1 (en) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 Novel nucleic acid prodrugs and methods of use thereof
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
EP2756080B1 (en) 2011-09-14 2019-02-20 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
EP2789347A4 (en) 2011-11-29 2015-12-16 Kowa Co Agent for inhibiting expression of npc1l1 and/or lipg mrna and agent for preventing and/or treating obesity
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
KR101835401B1 (en) 2012-07-13 2018-03-08 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. Chiral nucleic acid adjuvant
ES2940887T3 (en) 2012-07-13 2023-05-12 Wave Life Sciences Ltd Chiral Oligonucleotide Preparation Method
PL2872485T3 (en) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymmetric auxiliary group
DK2895200T3 (en) 2012-09-14 2020-02-10 Translate Bio Ma Inc MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
JPWO2015108048A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antitumor agent having antitumor activity
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
US10758558B2 (en) 2015-02-13 2020-09-01 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
CN115297838A (en) * 2020-02-24 2022-11-04 麦迪穆医学免疫有限责任公司 Formulations of anti-endothelial lipase antibodies
WO2024033465A1 (en) * 2022-08-10 2024-02-15 Boehringer Ingelheim International Gmbh Artificial mirnas targeting multiple hydrolases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
GB9413035D0 (en) * 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2273823C (en) * 1996-12-06 2007-06-05 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polypeptides encoded by a human lipase-like gene, compositions and methods
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
BR0009333A (en) * 1999-03-26 2002-01-08 Aventis Pharm Prod Inc Composition to reduce lipg gene expulsion and the enzymatic activity of the lipg polypeptide, to inhibit the enzymatic activity of the lipg polypeptide, to increase the level and enzymatic activity of the lipg polypeptide in a patient and methods to increase the cholesterol level of high density lipoprotein and apolipoprotein ai, to reduce the level of very low density lipoprotein cholesterol and ldl cholesterol and vldl cholesterol in a patient, to diagnose a predisposition to low levels of hdl cholesterol and apolipoprotein ai, and to determine whether a test compound can inhibit the enzymatic reaction between lipg polypeptide and hdl cholesterol and apolipoprotein ai and can increase the enzymatic reaction between lipg polypeptide and vldl and vdl cholesterol
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
CA2403243A1 (en) 1999-08-31 2001-03-08 Ribozyme Pharmaceuticals, Inc. Nucleic acid based modulators of gene expression
CA2492070A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Lung tumor marker pro4329 polypeptides and nucleic acids encoding the same
US20020177552A1 (en) 2000-06-09 2002-11-28 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
EP1539689A2 (en) * 2002-07-19 2005-06-15 Pharmacia Corporation Antisense modulation of endothelial lipase expression

Also Published As

Publication number Publication date
US20070020675A1 (en) 2007-01-25
WO2004055162A2 (en) 2004-07-01
US20040115653A1 (en) 2004-06-17
WO2004055162A3 (en) 2004-10-07
US20090156538A1 (en) 2009-06-18
AU2003300862A1 (en) 2004-07-09
US7507808B2 (en) 2009-03-24

Similar Documents

Publication Publication Date Title
AU2003300862A8 (en) Modulation of endothelial lipase expression
AU2003237875A1 (en) Antisense modulation of apolipoprotein b expression
AU2003295801A8 (en) Modulation of hif1alpha and hif2alpha expression
AU2003281324A8 (en) Antisense modulation of hmg-coa reductase expression
AU2003281327A1 (en) Antisense modulation of tfg-beta 2 expression
AU2003270066A8 (en) Modulators of angiogenesis
AU2001269123A1 (en) Regulation of human dipeptidyl-peptidase iv-like enzyme
AU2003215052A8 (en) Proteolytic fermenter
AU2003257966A1 (en) Antisense modulation of lar expression
AU2003272301A1 (en) Carotene-specific lipase
AU2003295790A8 (en) Modulation of iap-like expression
AU2003293078A8 (en) Modulation of b7h expression
AU2003243589A8 (en) Antisense modulation of smrt expression
AU2003241496A1 (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
AU2003295794A8 (en) Modulation of stat2 expression
AU2003287180A1 (en) Antisense modulation of gfat expression
AU2003293079A8 (en) Modulation of jagged 1 expression
AU2003230301A1 (en) Antisense modulation of dyrk4 expression
AU2003267790A8 (en) Lipase inhibitors and uses thereof
SI1569695T1 (en) Antisense modulation of apolipoprotein b expression
AU2003237211A1 (en) Antisense modulation of vegf-b expression
GB0213745D0 (en) Enzyme
AU2003295906A1 (en) ANTISENSE MODULATION OF mitoNEET EXPRESSION
EP1578942A3 (en) ANTISENSE MODULATION OF mitoNEET EXPRESSION
AU2003251530A1 (en) Antisense modulation of stati expression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase